This prospective, cross-sectional clinical trial was approved by the institutional review board of the University of British Columbia (UBC), Vancouver, British Columbia (BC), Canada (H18-02095), registered at clinical trials.gov (NCT03765112), and adhered to the tenants of The Declaration of Helsinki. Patients were recruited at the Department of Ophthalmology and Visual Sciences (UBC, Vancouver, BC, Canada) and written informed consent was obtained. Patients with type 1 or 2 diabetes mellitus (DM), DR of each severity level, and healthy controls were included. The following exclusion criteria were applied: media opacities, active intraocular inflammation, retinal disease other than DR like signs of age-related macular degeneration, drusen, retinal artery or vein occlusion, structural damage to the macula, macular edema with central retinal subfield thickness >290 μm in women and >305 μm in men measured with Spectralis OCT (Heidelberg, Jena, Germany), history of vitrectomy, glaucoma or use of intraocular pressure lowering eye drops, history of glaucoma surgery, intraocular surgery (including cataract surgery, YAG laser, panretinal laser photocoagulation, intravitreal injection of an anti-VEGF agent or corticosteroids) within 3 months prior to study inclusion. Medical history was obtained, including type of diabetes, duration of diabetes (defined by the start of antidiabetic medication), latest A1c level, height and weight, history of high blood pressure or ongoing anti-hypertensive medication use, history of cardiovascular events (including angina pectoris, myocardial infarction, bypass surgery, STENT implantation, ischemic cardiac disease, and stroke), smoking habits, history of ocular surgery, including lasers, and intravitreal injection therapies.